Escherichia coli (e Coli 0157 H7)

Overview

4.5 out of 5 (6 Reviews)

Credits

1.00

Pharmacology Credits

0.5

Post Assessment Questions

6

Start Date

1 Sep 2023

Last Review Date

1 Sep 2023

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Shiga toxin-producing Escherichia coli O157: H7, is an enterohemorrhagic bacterial strain that is an important food and a waterborne pathogen that causes diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome (HUS) in humans. Transmission is via the fecal-oral route after consumption of contaminated, undercooked liquids, foods, and by person-to-person through fecal shedding. The production of Shiga toxins is a key factor contributing to the development of a range of gastrointestinal illnesses, from watery diarrhea to hemorrhagic colitis and HUS. This activity outlines the evaluation and treatment of E.coli O157: H7 infection and highlights the role of the healthcare team in managing patients with this condition.

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Summerize the epidemiology of Escherichia coli O157: H7 infection.
  • Review the pathophysiology of Escherichia coli O157: H7 infection.
  • Outline the treatment and management options available for Escherichia coli O157: H7 infection.
  • Explain the importance of improving care coordination amongst the interprofessional team to enhance the delivery of care for patients with hemolytic uremic syndrome as a complication of Escherichia coli O157: H7 infection.
  • Outline the pharmacologic therapy as it applies to Escherichia coli (e Coli 0157 H7)

Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Nurse Practitioners: StatPearls designates this activity for 1.00 ANCC contact hour(s), which includes 0.5 hour(s) of pharmacology. NPs should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Elyshia L. on 10/18/2021

Dr.NIRMALA M. on 12/1/2022

Kevin C. on 1/3/2023

Susan c. on 3/23/2023

Tayebeh N. on 10/5/2023

Ehsan Q. on 10/7/2023

Unlimited Nurse Practitioner CE

Stay up to date on the latest medical knowledge with 6675 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7930 hours of CE.

Single Activity

Take this single activity

$49 1 activity

6 Month Unlimited Nurse Practitioner CE

Access to all the Unlimited Nurse Practitioner CE activities in all specialties.

$379 per half year per user

1 Year Unlimited Nurse Practitioner CE

Access to all the Unlimited Nurse Practitioner CE activities in all specialties.

$579 per 1 year per user